A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Elena Garralda(Memorial Sloan Kettering Cancer Center), Gerald S. Falchook(HealthONE), Martin Wermke(Hebron University), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yanyan Lou(Jacksonville College), Jane Healy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ravit Geva(Tel Aviv University), Sujata Jha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Seock‐Ah Im(Seoul National University Hospital), Amita Patnaik(South Texas Accelerated Research Therapeutics), Talia Golan(Tel Aviv University), Nehal J. Lakhani(Van Andel Institute), John Palcza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.3584
Cited by 46

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k